Last reviewed · How we verify
NCT04788108
Oral Progesterone for Prevention of Miscarriage in Threatened Abortion
Phase 4 trial testing Dydrogesterone in Threatened Abortion in 100 participants. Completed in 31 August 2022.
31 August 2022
Quick facts
| Lead sponsor | Chulalongkorn University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 1 August 2021 |
| Primary completion | 31 August 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Dydrogesterone (DYDROGESTERONE) — full drug profile →
- Placebo
Conditions studied
- Threatened Abortion — all drugs for Threatened Abortion →
Sponsor
Chulalongkorn University
Who can join
Adults 18 to 45, female only, with Threatened Abortion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04788108
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dydrogesterone
Trials testing the same drug.
- NCT05972902 — Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes · Phase 3 · unknown
- NCT05767086 — Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles · NA · completed
- NCT03859921 — Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET · Phase 3 · recruiting
- NCT03935152 — Oral Dydrogesterone in the Management of Preterm Labor · Phase 4 · completed
- NCT04287205 — The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis · NA · completed
Other Chulalongkorn University trials
Trials by the same sponsor.
- NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
- NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
- NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
- NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
- NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04788108 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
- Last refreshed: 30 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04788108.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing